Technology Description:
ARS researchers have developed a new inactivated Salmonella enteritidis (SE) oil emulsion vaccine that is superior to conventional commercial SE formulations. ARS's vaccine decreases the chance the bacterium will invade internal organs and substantially reduces the likelihood of SE being excreted in the feces. For a two dose strategy, the vaccine is applied 4-6 weeks following the initial dose. This oil emulsion formulation would likely have application against avian influenza, Newcastle disease, and other avian bacterial and viral pathogens.
SE is a major problem for the egg industry and consumers, since it can lead to Salmonella contamination of intact table eggs from infected flocks. Human illness from Salmonella poisoning can cause severe nausea, vomiting, abdominal cramps, and diarrhea. Vaccinating poultry is an important method to reduce SE problems in flocks. Approximately 25 million doses of SE vaccine are used annually in U.S. poultry and double to triple this amount is used overseas. Poultry breeding stock sold to overseas markets are required to be Salmonella free.
This invention could be used by egg producers, poultry breeder companies. Companies that develop poultry vaccines could develop this invention for commercial use. Foreign rights are available.
Reference:
Please refer to patent application S.N. 10/887,277 (Docket #0090.04), "Water-In-Oil Emulsion Vaccines," which was filed on July 8, 2004, and is a CIP of S.N. 10/101,943, which was filed on March 21, 2002. Foreign rights are not available.
Inventors:
Peter S. Holt Southeast Poultry Research Lab 934 College Station Road Athens, GA 30604-5677 (706) 546-3442 / Fax: (706) 546-3035 pholt@seprl.usda.gov |
Cam R. Greene (Same as first inventor) (706) 546-3433 / Fax: (706) 546-3035 cgreene@seprl.usda.gov
|
Henry D. Stone (Same as first inventor) (706) 546-3433 / Fax: (706) 546-3035 hstone@seprl.usda.gov |
|
|